Company: SNY
Filing Date: 2025-02-13
Form Type: 20-F
Source: 0001121404-25-000010
Chunk: 234

Company: Sanofi
Filing Date: 2025-02-13
Form: 20-F
Chunk 234
---
ofi’s scope of consolidation within the meaning of Article L. 233-16 of the French Commercial Code. Benefits in kind for 2025 comprise a company car with a driver. Compensation and benefits of all kinds awardable in respect of 2025 to Paul Hudson, Chief Executive Officer Fixed and variable annual compensation Acting on a recommendation from the Compensation Committee, the Board of Directors meeting of February 12, 2025 determined the components of Paul Hudson’s compensation for the 2025 financial year. Paul Hudson’s annual compensation comprises (i) annual fixed gross co mpensation of €1,600,000 (see the explanations provided under “— Compensation policy for corporate officers — Compensation policy for the Chief Executive Officer” above) and (ii) annual variable compensation in a range from 0% to 250% of his annual fixed compensation, with a target of 150%, and subject to both quantitative and qualitative criteria. The objectives are based 60% on financial indicators – sales growth, FCF and business EPS – each accounting for 20%. Floors have been set for each financial criterion, below which no variable compensation is payable for that criterion.

| Objectives based on financial indicators – unchanged for 2025 |     |              |     |
| 2025                                                          |     |         2024 |     |
| Sales growth                                                  | 20% | Sales growth | 20% |
| FCF                                                           | 20% |          FCF | 20% |
| Business EPS                                                  | 20% | Business EPS | 20% |
| TOTAL                                                         | 60% |              | 60% |

The structure of individual objectives was streamlined in 2024.

| 134 | SANOFIFORM 20-F2024 |

| PART I                                             |
| ITEM 6. Directors, Senior Management and Employees |

Individual objectives for 2025 and 2024 are shown below:

| 2025 individual objectives                                                                                                                                          |       | 2024 individual objectives *                                                                                                                                    |       |
| Business transformation(R&D Platform Optimization, Review of Manufacturing & SupplyOperating Model, Smart Spending, Asset Portfolio, Ongoing DigitalTransformation) | 15.0% | Business transformation(Reallocation of Pipeline Resources, Centralization, Hub Strategy,Smart Spending, Asset Portfolio, Digital Transformation)               | 15.0% |
| Development pipelineM1 (Lead selection), M2 (Candidate selection), First in Human,Pivotal Studies, Submissions, Approvals                                           | 15.0% | Development